Encision Reports First Quarter Results
BOULDER, Colo., July 27 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its first fiscal quarter ended June 30, 2010.
Net sales for the first quarter of fiscal year 2011, ended June 30, 2010, totaled $2.91 million, representing an 8% decrease from net sales of $3.17 million for the prior fiscal year's first quarter. The Company recorded a net loss of $119 thousand or $(0.02) per share for the first quarter of fiscal year 2011 compared to net income of $163 thousand or $0.03 per share for the first quarter of fiscal year 2010. Gross profit margin for the first quarter of fiscal year 2011 was 63.3% as compared to 64% for the first quarter of fiscal year 2010. The gross profit margin decrease in the first quarter of fiscal year 2011 was the result of higher manufacturing costs per unit of product as a result of decreased sales.
"We were disappointed with the downturn in our sales growth for the first quarter. However, we believe that the downturn is not endemic to Encision. Anecdotally, we understand that the number of laparoscopic and other medical procedures were down during the quarter, therefore resulting in lower sales for us and some of the other medical device companies," said Jack Serino, President and CEO of Encision Inc. "Looking forward, we recently entered an agreement with HealthTrust Purchasing Group, LP, a group purchasing organization and signed distribution agreements with distributors to sell our product lines in the United Kingdom, Ireland and Austria. We believe that at some point soon, the number of laparoscopic procedures will increase, thereby facilitating our path to continued sales growth."
Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2010 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, firstname.lastname@example.org
June 30, 2010
March 31, 2010
Cash and cash equivalents
Accounts receivable, net
Total current assets
LIABILITIES AND SHAREHOLDERS' EQUITY
Other accrued liabilities
Total current liabilities
Line of credit
Common stock and additional paid-in capital
Total shareholders' equity
Total liabilities and shareholders' equity
Three Months Ended
June 30, 2010
June 30, 2009
Cost of sales
Sales and marketing
General and administrative
Research and development
Total operating expenses
Operating income (loss)
Interest and other income (expense), net
Income before provision for income taxes
Provision for income taxes
Net income (loss)
Net income per share—basic and diluted
Basic and diluted weighted average number of shares
SOURCE Encision Inc.
More by this Source
Encision Reports Third Quarter Fiscal Year 2014 Results
Jan 30, 2014, 10:19 ET
Encision Files 510(k) with FDA for AEM® Simplification Product
Jan 08, 2014, 07:00 ET
Encision Completes $2 Million Private Placement of Common Stock
Dec 18, 2013, 07:05 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.